Evening all ..26 Jun 2018 23:30
How the Aim market sees value is intreguing .. for instance-
Scancell with mid phase 1 unprotected scib1, and just a discovered unprotected moditope and no top industry contacts or colleagues - value just over £100M
Scancell with phase 1/2 worldwide patented scib 1 completed with 'out of the ball park' Beyond 5 year survival (cure?) data, scib2 phase 1/2 paid for, a protected moditope platform, a protected Glycan platform, a route into tcr technology with bioNTech plus a raft of thought leaders and industry experts gathering for project blueprint and £20M possible injection into modi3 - value £51M !!
Guess what folks .. I'm still hoarding !!
Take care all .. just a few thoughts !